Blog

Bernard A. Fox: Speaking at Nyulangone Medical Center at the celebration of the life and legacy of Jeffrey S. Weber

Bernard Fox/Chiles Research Institute-X

Nov 18, 2024, 10:06

Bernard A. Fox: Speaking at Nyulangone Medical Center at the celebration of the life and legacy of Jeffrey S. Weber

Bernard A. Fox, Co-Founder, President, and CEO of UbiVac, shared a post on LinkedIn:

“It was an honor for me to join many esteemed colleagues and speak today at NYULANGONE MEDICAL CENTER at the celebration of the life and legacy of Jeffrey S. Weber, MD, PHD. An internationally recognized Melanoma immunotherapy GURU & ROCKSTAR, Jeff dedicated his life to his patients, the development of better treatment options, and to training the next generation of cancer Immunotherapists.

In addition to all that, he was also a dear friend to me and many in the field, as was clear from the recollections of the assembled speakers. Cancer got Jeff before his time, and as his wife noted, it underscores how much more we need to do.

I agree! We need to continue to push the envelope!

Those of us in positions to move the field need to continue pushing!

Thanks Iman Osman, Mace Rothenberg, Dr. Klec kimmelman, David Cohan, Omid Hamid, James Mule, Hussein Tawbi, Michelle Krogsgaard, Janice M. Mehnert, Dr. Richard Shapiro, Society for Immunotherapy of Cancer(SITC), American Society of Clinical Oncology (ASCO), AACR Journals, ESMO – European Society for Medical Oncology, Melanoma Research Alliance, Melanoma Institute, Australia Melanoma Research Foundation, Bristol Myers, Squibb Agenus Inhibrx Biosciences, Inc., Regeneron Moderna, Paolo A. Ascierto, Merck Fondazione, Melanoma, UbiVac, Incyte, Amgen, Pfizer ,AstraZeneca, Merck Group Bayer, National Cancer Institute (NCI), Israel Lowy Steven O’Day, Lothar H Finke.”

Bernard A. Fox: Speaking at Nyulangone Medical Center at the celebration of the life and legacy of Jeffrey S. Weber

Bernard A. Fox is the Co-Founder, President, and CEO of UbiVac. He is an Adjunct Professor in the Department of Molecular Microbiology and Immunology, at the Knight Cancer Institute. He is also a Member of Board of Directors at Oregon Bioscience Association.In 2012, Dr. Fox received the Harder Family Endowed Chair for Cancer Research in recognition of his efforts in translational cancer therapy.